Phenotype News and Research

RSS

CEAT project for improving ovarian cancer diagnosis, treatment shows promise

Porvair Sciences reports, due to promising results, it has agreed with its collaborative partners to make additional investment in the CEAT project which aims to dramatically improve the diagnosis and treatment of ovarian cancer.

From Porvair Sciences Limited 16 Nov 2020

Study explains why anti-inflammatory drugs benefit only few people with severe COVID-19

The turning point for people with COVID-19 typically comes in the second week of symptoms. As most people begin to recover, a few others find it increasingly difficult to breathe and wind up in the hospital.

16 Nov 2020

Researchers identify prognostic markers that could guide COVID-19 management

A team of researchers in Europe has created a comprehensive data resource to help improve understanding of how coronavirus disease 2019 (COVID-19) progresses and how biomarkers could be used to guide treatment approaches and disease monitoring.

15 Nov 2020

Men and women may require different brain tumor therapy, study finds

The current study shows that the sex differences in the tumor phenotype vary with the effect of the enhancer regulatory molecule bound to Brd4 on the course of stem cell-like differentiation in male and female GBM cells. Inhibition of Brd4 by genetic and pharmacological factors also varies in males and females, both in vivo and in vitro.

11 Nov 2020

Researchers identify new prognostic markers for colon cancer

The gut-associated lymphoid tissue represents an integral part of the immune system. Among the powerful players of the mucosa-associated lymphoid tissue are isolated lymphoid structures (ILSs).

11 Nov 2020

Pioneering technique sheds new light on the origin of metastases

Research can now target metastases more effectively thanks to a new approach that takes into account the enormous heterogeneity and phenotypes of tumor cells, with a team from UNIGE pinpointing a gene that prevents their development.

10 Nov 2020

Severe COVID-19 linked to age, body mass index and ABO blood group

With the COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting over 50 million people worldwide with hundreds of thousands experiencing severe respiratory illness, researchers have been trying to find the factors associated with severe disease. From the start of the pandemic in March this year, several studies have indicated heart disease, high blood pressure, diabetes, obesity, etc. could be linked to severe disease. Now German researchers have published a study on the association between severe respiratory infection caused by SARS CoV-2 and factors such as age, body mass index (BMI) and ABO blood group.

10 Nov 2020

Majority of population likely has pre-existing immunity to SARS-CoV-2, claim researchers

A team of researchers has conducted a study suggesting that the majority of the global population is likely to have pre-existing T-cell immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic.

9 Nov 2020

Patients diagnosed with Parkinson's disease may actually have NIID, shows study

A joint study by the National Neuroscience Institute (NNI) and Singapore General Hospital (SGH) revealed that patients who have been diagnosed with Parkinson's disease might actually have NIID instead.

9 Nov 2020

Reducing the airborne transmission risk for SARS-CoV-2

Rapid Reviews: COVID-19 (RR:C19), an open-access overlay journal published by the MIT Press that accelerates peer review of COVID-19-related research preprints, is currently soliciting reviews of the following COVID-19 preprints.

6 Nov 2020

Most SARS-CoV-2-infected individuals develop durable B cell-mediated immunity

Researchers from the Johns Hopkins University and The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA, investigated the durability of B cell immunity following SARS-CoV-2 infection and recovery in their recent work published on the preprint server medRxiv.

3 Nov 2020

SARS-CoV-2 T-cell immunity is retained for at least six months

Now, a new study published on the preprint server bioRxiv shows that functional SARS-CoV-2-specific T-cell responses are retained for six months following infection. However, the strength of this response depends on the clinical features of the primary infection.

3 Nov 2020

Study identifies structural, functional brain differences in people with occupational blast exposure

Military and law enforcement personnel with extensive occupational blast exposure had statistically significant differences in brain imaging measures compared to nonexposed control personnel.

3 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

MD65 IgG-YTE shows powerful post-exposure neutralization of SARS-CoV-2

A recent study published in the preprint server bioRxiv in October 2020 describes a reliable animal model to demonstrate the powerful capacity of human neutralizing mAbs directed against SARS-CoV-2 to prevent viral binding the host cell receptor and thus block infection. This indicates the lifesaving value of mAbs in severe COVID-19.

29 Oct 2020